Government of Canada / Gouvernement du Canada
Symbol of the Government of Canada

Search

Food and Drug Regulations

Version of section C.02.019 from 2006-03-22 to 2013-11-07:

  •  (1) Subject to subsections (3) and (4), in the case of a packager/labeller, distributor referred to in paragraph C.01A.003(b) or importer, the testing referred to in section C.02.018 shall be performed on a sample taken

    • (a) after receipt of each lot or batch of the drug on the premises in Canada of the packager/labeller, distributor referred to in paragraph C.01A.003(b) or importer of the drug; or

    • (b) subject to subsection (2), before receipt of each lot or batch of the drug on the premises described in paragraph (a), if

      • (i) the packager/labeller, distributor referred to in paragraph C.01A.003(b) or importer

        • (A) has evidence satisfactory to the Director to demonstrate that drugs sold to him by the vendor of that lot or batch of the drug are consistently manufactured in accordance with and consistently comply with the specifications for those drugs, and

        • (B) undertakes periodic complete confirmatory testing with a frequency satisfactory to the Director, and

      • (ii) the drug has not been transported or stored under conditions that may affect its compliance with the specifications for that drug.

  • (2) Where the packager/labeller, distributor referred to in paragraph C.01A.003(b) or importer of a drug receives a lot or batch of the drug on their premises in Canada, and the useful life of the drug is more than 30 days, the lot or batch shall be tested for identity, and the packager/labeller shall confirm the identity after the lot or batch is packaged/labelled.

  • (3) The distributor referred to in paragraph C.01A.003(b) of a drug that is fabricated, packaged/labelled and tested in Canada by a person who holds an establishment licence that authorizes those activities is not required to comply with the requirements of subsections (1) and (2) in respect of that drug.

  • (4) If a drug is fabricated, packaged/labelled and tested in an MRA country at a recognized building, the distributor referred to in paragraph C.01A.003(b) or importer of that drug is not required to comply with the requirements of subsections (1) and (2) in respect of that drug if

    • (a) the address of the building is set out in that person’s establishment licence; and

    • (b) that person retains a copy of the batch certificate for each lot or batch of the drug received by that person.

  • SOR/82-524, s. 3
  • SOR/89-174, s. 8(F)
  • SOR/97-12, ss. 16, 57
  • SOR/2000-120, s. 11
  • SOR/2002-368, s. 10
Date modified: